Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Stephen D. Wilson who wrote (776)	5/7/1998 4:53:00 PM
From: cm	Read Replies (1) \| Respond to of 1491

I'd Like To Second That... Having gotten into a few SI thread wars myself, some where I was completely in the wrong and others where I was not, I wish, David, that you would reconsider your departure. I've read each of your posts for quite a while... and have thought of you, rightly or wrongly, as an interested and informed advocate for those of us who are PARS LONGs. Very seldom (just a handful of posts, largely because of PARS "undiscovered" status) have I come across any blind boosterism on this thread. Which is not to say that just because one is LONG and has insights and ready access to information that ONE is immunized against cordial, good-spirited questioning and debate. In any case, you don't know me so my words will probably carry very little weight with you. But, I would like to second Stephen's comments. And, in any case, wish you and all of us nothing but success with our PARS investments. However, should you choose to stay away... this will be, IMHO, a loss to this thread. Best Regards, c m

To: Stephen D. Wilson who wrote (776)	5/7/1998 6:16:00 PM
From: Gabe Fernandez	Read Replies (2) \| Respond to of 1491

TO ALL: lets stop the controversy and analyze the new facts 1-completion of second dose study. 2-start of the third phase study. 3- Company plans to unbind the results this summer (time factor given) 4-12%mortality rate officially given (50% reduction). Consider 7/32 up is a nice % up on a 2.85 stock, the lack of better response could be attributed to the smallness of the company. If i did not know anything about Pars an my broker called me about this report i would do some personal analysis prior to purchasing. Remember we know the co better than most investors, the fact research is in a foreign country adds to the possible skepticism. Lets all hang together and enjoy